Inovio Pharmaceuticals Inc vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Direxion Daily Semiconductor Bull 3X Shares trades at $154.21. The key difference: Direxion Daily Semiconductor Bull 3X Shares is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SOXL | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $2.87 | $300.77 |
52-Week Low | $1.05 | $23.99 |
Enterprise Value | $60.28M | — |
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
SOXL trades at $136.81, up 1.24% on the day, amid a bearish technical signal with 17 sell indicators versus 7 buy. The semiconductor sector faces volatility, with recent news highlighting AI-driven demand potential but also capital expenditure concerns from major holdings like TSMC. Support sits at $127, with resistance at $144, indicating a critical juncture for near-term price action.
The outlook remains cautious due to leveraged ETF decay risks and sector-wide headwinds, though AI infrastructure growth offers long-term opportunity. Investors face elevated volatility from semiconductor cycle swings and competitive pressures, requiring careful risk management given the fund's amplified exposure.
Trailing returns across standard periods
Latest headlines on both assets
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →